BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Vassilopoulos D, Calabrese LH. HCV Treatments and Their Integration Into Rheumatology. Curr Rheumatol Rep 2015;17. [DOI: 10.1007/s11926-015-0526-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 McGrath B, Broadhurst M, Roman C. Infectious disease considerations in immunocompromised patients. JAAPA 2020;33:16-25. [PMID: 32841972 DOI: 10.1097/01.JAA.0000694948.01963.f4] [Reference Citation Analysis]
3 Md Yusof MY, Vital EM, Buch MH. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Curr Rheumatol Rep 2015;17:65. [PMID: 26290110 DOI: 10.1007/s11926-015-0539-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]